Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Aptevo Therapeutics Inc. (APVO)

Aptevo reports substantial cut in infusion-related reactions with mipletamig in AML trial

Neutral Impact 3 of 5 product/contract Written later

Aptevo Therapeutics said successive refinements to the priming-dose regimen for its lead candidate, mipletamig, substantially reduced infusion-related reactions in the ongoing RAINIER study in frontline acute myeloid leukemia. The company said the change supports its preparation for Phase 2 development, which it expects to initiate in 2027, but the filing gives no numerical measure of the reduction and states that the findings do not establish improved efficacy.

Key points

  • Successive priming-dose refinements substantially reduced infusion-related reactions, per the press release; no reduction percentage is disclosed.
  • Mipletamig data will be presented at the ASH 68th Annual Meeting, December 12-15, 2026, in New Orleans.
  • Aptevo expects to complete the RAINIER study by year-end 2026 and initiate Phase 2 development in 2027.

The filing

CompanyAptevo Therapeutics Inc. (APVO)
Form8-K, current report
Filed with the SECNov 5, 2026, 8:35 AM ET
Accession number0001193125-26-448714

Items reported: 8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 05, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.